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Abstract
Occupational exposure to formaldehyde has been linked to nasopharyngeal carcinoma. To date,
mechanistic explanations for this association have primarily focused on formaldehyde-induced
cytotoxicity, regenerative hyperplasia and DNA damage. However, recent studies broaden the
potential mechanisms as it is now well established that formaldehyde dehydrogenase, identical to
S-nitrosoglutathione reductase, is an important mediator of cGMP-independent nitric oxide
signaling pathways. We have previously described mechanisms by which formaldehyde can
influence nitrosothiol homeostasis thereby leading to changes in pulmonary physiology.
Considering evidences that nitrosothiols govern the Epstein-Barr virus infection cycle, and that the
virus is strongly implicated in the etiology of nasopharyngeal carcinoma, studies are needed to
examine the potential for formaldehyde to reactivate the Epstein-Barr virus as well as additively or
synergistically interact with the virus to potentiate epithelial cell transformation.
Introduction
The International Agency for Research on Cancer (IARC)
has classified formaldehyde as a human carcinogen based,
in part, on epidemiological evidence that formaldehyde
increases the risk of nasopharyngeal carcinoma (NPC) [1-
4]. This cancer exhibits remarkable geographical distribu-
tion that is posited to result from environmental factors,
host genetic factors (i.e. race), and genetic variation in the
gammaherpesvirus Epstein-Barr virus (EBV) that is widely
believed to play a role in the etiology of NPC [5-9]. Mech-
anisms posited to explain formaldehyde carcinogenicity
have invoked evidence for cytotoxicity, compensatory cell
proliferation, and genotoxicity in animal bioassays [4,10-
13]. However, mathematical models of the human respi-
ratory passages indicate that the highest doses of formal-
dehyde are predicted to be above the hard palate, with
relatively less vapor reaching the nasopharynx [14]. His-
topathological samples from workers exposed to formal-
dehyde exhibit only mild nasal tissue pathology [4,15],
suggesting that tissue damage might not occur in more
distal regions. Thus, available data do not paint a coherent
mechanism for formaldehyde to increase the risk of NPC,
and moreover the association continues to be disputed
[16-18].
Few articles published on formaldehyde toxicity over the
past decade have acknowledged that the class III alcohol
dehydrogenase (ADH3), also termed formaldehyde dehy-
drogenase and S-nitrosoglutathione (GSNO) reductase, is
a key mediator of the nitric oxide (NO)-related post-trans-
lational protein modification known as S-nitrosylation
(Figure 1a) [19-24]. The S-nitrosylation of protein
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cysteine residues by NO and GSNO regulates a broad
spectrum of cellular proteins and functions [25-36]. Dys-
regulation of nitrosothiol homeostasis has been impli-
cated in diseases of the central nervous system,
cardiovascular system, and lung [37-43]. We have previ-
ously described how ADH3 and nitrosothiols influence
pulmonary physiology, and how formaldehyde might
influence nitrosothiol homeostasis [24,44,45]. Consider-
ing that nitrosothiols are implicated in the regulation of
EBV and other viruses [28,29,32,46], herein we describe
mechanisms by which formaldehyde might influence the
reactivation of the EBV and additionally interact with EBV
latency programs to potentiate epithelial cell transforma-
tion.
Simplified hypothetical model for formaldehyde interaction with EBV Figure 1
Simplified hypothetical model for formaldehyde interaction with EBV. a) Alcohol dehydrogenase 3 (ADH3) cata-
lyzes the oxidation of GSH-conjugated formaldehyde (S-hydroxymethylglutathione, HMGSH) to S-formylglutathione (FGSH), 
and the reduction of GSH-conjugated NO (S-nitrosoglutathione, GSNO) to glutathione sulfinamide (GSONH2). Both NO and 
GSNO regulate protein function by S-nitrosylating cysteine residues, albeit with differential specificity. Excessive formaldehyde 
can accelerate GSNO reduction via NAD+/NADH cofactor recycling leading to decreased cellular nitrosothiols. Interleukin-13 
has recently been shown to increase ADH3 expression. b) EBV latency programs that contain LMP1 promote latency, in part, 
through activation of NF-κB pathways. NO appears to be required for latency in programs that lack LMP1, as NOS inhibition 
can reactivate the EBV in vitro. Similar to LMP1, this process likely involves activation of NF-κB. This NO-mediated regulation 
of EBV is cGMP-independent and involves S-nitrosylation of RAS by NO and/or GSNO. In addition, binding of the early lytic 
transcription factor, Zta, to DNA is inhibited by redox and nitrosative modification of cysteine residues. c) Nitrosothiols influ-
ence the EBV life cycle. Increased ADH3 expression or excessive formaldehyde exposure from xenobiotic metabolism (e.g. N-
nitrosodimethylamine, NDMA) or exogenous sources may accelerate GSNO reduction thereby promoting EBV reactivation. 
Zta may also increase IL-13, which may in turn increase ADH3 expression. In addition to EBV reactivation, formaldehyde medi-
ated protein modification and DNA reactivity can interact with established EBV latency programs to promote epithelial cell 
transformation.Environmental Health 2009, 8:53 http://www.ehjournal.net/content/8/1/53
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Discussion
(a) The EBV Life Cycle and NPC
The World Health Organization has periodically classified
NPC based on histology, yet all NPC appears to be vari-
ants of squamous cell carcinoma [5]. Though NPC risk
varies geographically, nearly all cases and types of NPC
demonstrate EBV-positive cells and thus EBV is strongly
implicated in the etiology of NPC [5,7,8]. Over 90% of the
population is EBV positive, yet EBV is rarely detected in
normal human epithelial biopsies, and when it is
detected, it is almost always in carcinomas and in the
latent phase [6,8,47]. The EBV exhibits three latency pro-
grams [48]. Latency III is the least restrictive and involves
the expression of six nuclear antigens (EBNA1-6), three
latent membrane proteins (LMP1, LMP2A, and LMP2B),
and untranslated nuclear RNAs. Latency I is the most
restrictive and expresses LMP2A and EBNA1 and is associ-
ated with memory B-cells. The Latency II program
expresses EBNA1 and the three LMPs, and is the program
associated with NPC [48]. These latency programs and
other factors compete to repress and promote the activity
of the EBV lytic transcription factor Zta [47]. Importantly,
both EBV reactivation and EBV latency programs are
thought to contribute to the etiology of NPC [6,8,49-52].
The former process may increase the risk of infection to
target epithelial cells, whereas the latter may increase the
risk of cell transformation. The potential influence of for-
maldehyde on these processes is described in the sections
that follow.
(b) Nitrosothiols Influence the EBV Life Cycle
In 1968, the EBV was reported to be reactivated in cells
cultured in media deficient in the nonessential amino
acid and NO precursor L-arginine [53]. Over 25 years
later, NO synthase (NOS) inhibitors were shown to reac-
tivate EBV in human lymphocytes exhibiting Type I
latency but not Type III [29]. This specificity was posited
to relate to the fact that LMP1 (not present in Type I
latency) and NO converge on similar signaling pathways
such as NF-κB [29,34]. NO also prevented B-cell apopto-
sis, which is consistent with evidence that LMP1 promotes
uncontrolled B-cell proliferation [29,48]. This suppres-
sion of the lytic phase and apoptosis by NO was report-
edly mediated through cGMP-independent signaling
pathways, and likely involves nitrosothiol modification of
p21 Ras [29,34,54]. NO also suppresses the lytic phase of
EBV in epithelial cell lines; and moreover, the established
induction of EBV reactivation by TPA (12-O-tetrade-
canoylphorbol-13 acetate) coincided with decreased lev-
els of NOS [55]. It is also noteworthy that NO inhibition
increased the expression of the early lytic transcription
factor Zta in both lymphocytes and epithelial cells
[29,55]. The binding of this viral transcription factor to
DNA is reported to be inhibited by both redox and nitro-
sative mechanisms that involve critical cysteine residues
[28]. Interestingly, Zta is reported to induce the expression
of interleukin-13, which may in turn up-regulate ADH3
[56,57]. Although further studies are needed to examine
these responses together in individual cell types and in in
vivo systems, the data suggest that nitrosothiol homeosta-
sis plays a dual role in promoting the latent phase and
inhibiting the lytic phase of the EBV in lymphocytes and
epithelial cells expressing certain latency programs (Figure
1b).
To date, little is known about what conditions might lead
to altered nitrosothiol homeostasis in vivo. It is becoming
increasing clear, however, that environmental exposures
to allergens can elevate ADH3 expression in airways
thereby decreasing nitrosothiol levels sufficiently to cause
patent changes in pulmonary physiology [41,57,58].
Moreover, evidence suggests that exposure to relatively
high levels of formaldehyde vapor can lead to immune
responses, elevated ADH3, and increased GSNO break-
down in rodent airways [45,59,60]. Additionally, formal-
dehyde can accelerate GSNO reduction several fold in cell
and cell-free systems through NAD+/NADH cofactor recy-
cling on ADH3, as well as decrease cellular nitrosothiol
levels in vitro (Figure 1a)) [61,62]. Together, these data
suggest that formaldehyde can accelerate GSNO reduc-
tion, which might promote EBV reactivation in cells lining
the airways (Figure 1c). This reactivation, in turn, could
lead to increased viral shedding in nasopharyngeal lym-
phocytes and subsequent infection of basal epithelial cells
[8]. It is notable, though circumstantial, that the relative
risk of NPC among occupationally exposed workers is
reported to be stronger among EBV seropositive individu-
als [2].
(c) EBV Latency and Cell Transformation
Several mechanisms are implicated in EBV-mediated cell
transformation. EBNA1, EBNA2, and LMP1 have all been
shown to induce oxidative stress, genomic instability, or
DNA repair inhibition [63-66]. In fact, LMP1 is posited to
be an important oncogene and a key modulator in the
pathogenesis of NPC through activation of NF-κB signal-
ing pathways related to cell cycle control, apoptosis and
transformation [51]. LMP1 acts as a ligand-independent
CD40 receptor that functions, in part, by preventing the
ubiquitination of TNF-receptor associated factors [50].
Other EBV proteins manipulate the fate of host proteins
by accelerating or decelerating their degradation through
the ubiquitin-proteosome system, while simultaneously
decelerating their own ubiquitination and degradation
[50,67]. These myriad effects imparted by EBV latency
programs likely perturb many cellular functions in subtle
ways that can increase spontaneous transformation or
otherwise potentiate cells for transformation. As noted
previously, the etiology of NPC involves host, viral and
environmental factors. Considering that the functions ofEnvironmental Health 2009, 8:53 http://www.ehjournal.net/content/8/1/53
Page 4 of 6
(page number not for citation purposes)
many proteins may be modulated by S-nitrosylation, it is
conceivable that excess formaldehyde exposure may fur-
ther alter protein functions in EBV-positive cells. Addi-
tionally, formaldehyde itself can deplete GSH levels and
can react with proteins and peptides [68-70]. Recent
genomics analyses in yeast cells clearly indicate that oxi-
dative stress pathways are induced by formaldehyde expo-
sure [70]. These analyses also identified protein fate
(processing and degradation, folding and stabilization,
and ubiquitination pathways) as a major category of
altered gene expression; formaldehyde induced 14-19%
of genes involved in ubiquitination processes, whereas
methanol (which is oxidized to formaldehyde) induced
only 1% of these genes [70]. While this simple eukaryotic
system may not directly inform in vivo mammalian tissue
responses, there is little reason to believe that it cannot
provide sentinel information as to how formaldehyde
interacts with cellular macromolecules. These effects on
protein function may partially explain the synergistic
effect formaldehyde has on genetic damage in mamma-
lian cells [71,72]. Moreover, such effects on proteins may
explain the association between NPC and consumption of
salted fish containing nitrosamines like N-nitrosodimeth-
ylamine, as the cytochrome P450-mediated oxidation of
these compounds can generate formaldehyde (Figure 1c)
[5,7,73-76].
Conclusion
NPC is a multifactorial disease thought to involve host,
viral, and environmental factors. Evidence for an associa-
tion between NPC and occupational exposure to formal-
dehyde remains debated, despite its classification as a
human carcinogen [1-4,16-18]. Data described herein
indicate that NO, acting through cGMP-independent
pathways, can influence the EBV life cycle. As such, exces-
sive environmental exposure to formaldehyde might per-
turb nitrosothiol homeostasis and potentiate EBV
reactivation - thereby increasing the chance of basal epi-
thelial cell infection. Data also suggest that protein stabil-
ity and degradation are significantly affected by
formaldehyde exposure; such changes might arise from
direct formaldehyde modification of proteins, redox
changes, or altered protein nitrosylation. Thus, concomi-
tant with multiple perturbations caused by EBV latency
programs, formaldehyde might additionally act additively
or synergistically with EBV to promote epithelial cell
transformation. Future investigations on these mecha-
nisms may shed additional light as to the plausibility of
epidemiological associations between formaldehyde
exposure and NPC. Finally, the mechanisms presented
herein might also be operative for other diseases associ-
ated with formaldehyde exposure that have etiologies
involving EBV, such as lymphoproliferative disorders.
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